logo
  

SQI Diagnostics : FDA Stops EUA Review Of RALI-Dx IL-6 Severity Triage Test For COVID-19 Patients

SQI Diagnostics Inc.(SQD.V, SQIDF), a Canadian precision medicine company that develops rapid diagnostic testing, said that U.S. Food and Drug Administration will not continue its review of the company's submission of the RALI-Dx IL-6 Severity Triage Test for Emergency Use Authorization under the "Tests for Management of COVID-19 Patients" category.

The FDA cites a high volume of EUA requests and its prioritization of EUA reviews according to factors including the public health need for the product and shortages of critical devices during the pandemic.

However, the FDA has asked SQI to submit an application under a non-EUA regulatory pathway.

The RALI-Dx IL-6 Severity Triage Test has broad applicability in helping to identify patients with severe inflammatory response arising from COVID-19 and other causes of respiratory distress.

SQI said it is confident that the FDA prioritization will support its upcoming COVID-19 HOME Antibody Test submission under the EUA regulatory pathway.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Company (GE) said it delivered a strong third quarter as orders grew, and margins continued to improve from a year ago. Adjusted GE Industrial organic profit increased 54% year-on-year, organically, driven primarily by increases at Aviation and Power, partially offset by decreases at... Ward Hill, Massachusetts-based Cedar's Mediterranean Foods is recalling Cedar's Organic Mediterranean Hommus citing undeclared pine nut, an allergen, the U.S. Food and Drug Administration said. The Cedar's Organic Mediterranean Hommus is packaged in a 10 oz. plastic container, with a UPC Code: 044115403028. Shares of UBS Group AG were gaining around 2 percent in Swiss trading after the banking major reported Tuesday higher profit in its third quarter with growth in net interest income. Further, the company said it intends to repurchase up to $0.6 billion of shares during the fourth quarter. The company will provide strategic update on February 1, 2022.
Follow RTT